TickerFacts.

Zura Bio Ltd (ZURA): Total Liabilities

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2022-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$12.41M
As of 2025-12-31
$16.32M
As of 2026-06-30
-5.7%
3-year compound annual growth
$21.29M2021-12-31: $10.35M2022-12-31: $14.82M2023-12-31: $21.29M2024-12-31: $19.51M2025-12-31: $12.41M$12.41M
2021-12-31 Total Liabilities (USD) 2025-12-31
Period endedTotal LiabilitiesChange YoYSource filing
2025-12-31$12.41M-36.4%2026-03-19, Balance as of period end
2024-12-31$19.51M-8.4%2026-03-19, Balance as of period end
2023-12-31$21.29M+43.7%2025-03-25, Balance as of period end
2022-12-31$14.82Mn/c2024-03-28, Balance as of period end
2021-12-31$10.35Mn/a2023-03-28, Balance as of period end

Total Liabilities at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal LiabilitiesChange YoY
Zura Bio Ltd (ZURA)2025-12-31$12.41M-36.4%
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31$69.24M+91.2%
Humacyte, Inc. (HUMA)2025-12-31$113.26M-40.6%
Kalaris Therapeutics, Inc. (KLRS)2025-12-31$42.92M-24.4%
Acumen Pharmaceuticals, Inc. (ABOS)2025-12-31$52.40M-8.3%
Anavex Life Sciences Corp. (AVXL)2025-09-30$8.95M-41.5%
Candel Therapeutics, Inc. (CADL)2025-12-31$73.27M+80.7%
Pelthos Therapeutics Inc. (PTHS)2025-12-31$91.52Mn/m
Artiva Biotherapeutics, Inc. (ARTV)2025-12-31$20.97M-8.6%

Compare ZURA, LCTX, HUMA, KLRS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗